BSE filing, NSE: GLENMARK. Summary written from the filing by ALFA Finder's alert engine.
Glenmark Pharmaceuticals Ltd: key numbers
- Share price
- ₹2,339.00
- Market cap
- ₹66,012 Cr
- Revenue (annual)
- ₹16,983 Cr
- Net profit (annual)
- ₹1,362 Cr
- P/E (TTM)
- 36.7×Sector 48.7×
- Promoter holding
- 46.65%+0.00% QoQ
- FII holding
- 21.51%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Glenmark Pharmaceuticals Ltd
All →Glenmark Pharmaceuticals Board Meeting Date
Glenmark Pharmaceuticals notified BSE of a board meeting on 05 Nov 2026 to consider unaudited Q2 FY27 results. No financial figures are disclosed in this advance intimation.
Glenmark Pharmaceuticals Other Announcement
Glenmark Pharmaceuticals has filed its quarterly shareholding pattern for the period ended September 30, 2026, as required under SEBI Regulation 31(1)(b).
Glenmark Pharmaceuticals Product Launch
Glenmark Pharmaceuticals launched Adapalene Gel USP, 0.1% (OTC) in new pump packs in the USA, expanding its dermatology portfolio.
Glenmark Pharmaceuticals Business Update
Glenmark Pharmaceuticals received an Establishment Inspection Report from the U.S. FDA for its Goa facility, which has been assigned a Voluntary Action Indicated status.
Glenmark Pharmaceuticals Annual General Meeting
Glenmark Pharmaceuticals held its 48th Annual General Meeting on September 11, 2026. The company submitted the proceedings, Scrutinizer’s Report, and voting results to the exchanges.
Glenmark Pharmaceuticals Product Launch
Glenmark Pharmaceuticals launched RYALTRIS® nasal spray in Brazil to treat moderate to severe allergic rhinitis, expanding its global respiratory product footprint in Latin America.
Other debt & borrowing announcements
All →QGO Finance Debt & Borrowing: ₹1 Cr
QGO Finance Ltd has redeemed 100 unlisted non-convertible debentures, with a total value of Rs. 1 Crore, including the principal and applicable interest.
- Value
- ₹1.00 Cr
Capri Global Capital Debt & Borrowing: ₹1.42 Cr
Capri Global paid interest on four listed NCD series ahead of their due dates, totalling Rs.1.42 Crore. The Reg 57 certificate reports no payment changes or delays.
- Value
- ₹1.42 Cr
Ugro Capital Debt & Borrowing: ₹2.99 Cr
Ugro Capital paid Rs 2.99 Crore in interest on two NCD series on 29 October 2026. Payments were made a day before the 30 October due date.
- Value
- ₹2.99 Cr
Time Technoplast Debt & Borrowing: ₹50 Cr
Time Technoplast redeemed its Rs.50 Crore commercial paper in full on maturity on 29 October 2026. The redemption completes servicing of this short-term debt instrument.
- Value
- ₹50.00 Cr
Samvardhana Motherson International Debt & Borrowing: ₹834.8 Cr
Samvardhana Motherson issued a corporate guarantee for a EUR 75 million BNP Paribas term facility of subsidiary MGI B.V. Liability capped at ₹834.75 Crore.
- Value
- ₹834.8 Cr
- Execution
- Guarantee valid up to February 28, 2032
Electrotherm (India) Debt & Borrowing: ₹59.81 Cr
Electrotherm disclosed a Rs 59.81 Crore default on bank loans as at 30 September 2026. The loans were assigned to an ARC under a settlement.
- Value
- ₹59.81 Cr